Eltrombopag Olamine

The dosage of Eltrombopag Olamine is highly individualized and depends on the specific condition being treated, the patient's baseline platelet count, and their ancestry.

• Chronic ITP: The typical starting dose for most adults is 50 mg once daily. However, for patients of East Asian ancestry (such as Chinese, Japanese, Taiwanese, or Korean) or those with mild to severe hepatic impairment, the starting dose is usually reduced to 25 mg once daily.
• Chronic Hepatitis C: The starting dose is almost always 25 mg once daily for all patients. The dose is then adjusted in 25-mg increments every 2 weeks to achieve the target platelet count required to initiate antiviral therapy.
• Severe Aplastic Anemia (Refractory): The starting dose is 50 mg once daily, with a reduction to 25 mg for patients of East Asian ancestry or those with liver impairment.
• Severe Aplastic Anemia (First-line): When used with immunosuppressive therapy, the dose is often higher (up to 150 mg once daily for 6 months), though this depends on the specific protocol prescribed by the hematologist.

Eltrombopag Olamine is approved for children with chronic ITP who are 1 year of age or older.

• Ages 6 to 17 years: The starting dose is typically 50 mg once daily (25 mg for those of East Asian ancestry).
• Ages 1 to 5 years: The starting dose is 25 mg once daily, regardless of ancestry.
• Severe Aplastic Anemia: For children 2 years and older, dosing is based on body weight and specific clinical protocols.

Renal Impairment

No specific dose adjustment is generally required for patients with renal impairment, though clinical monitoring should be more frequent as the drug's metabolites are partially cleared through the kidneys.

Hepatic Impairment

Because Eltrombopag is primarily metabolized and excreted via the liver, patients with hepatic impairment (Child-Pugh Class A, B, or C) are at a higher risk of toxicity. A lower starting dose (usually 25 mg) is mandatory, and liver function tests must be monitored weekly during the dose-adjustment phase.

Elderly Patients

Clinical trials did not show overall differences in safety or effectiveness between patients over 65 and younger patients. However, because elderly patients are more likely to have decreased hepatic or cardiac function, healthcare providers often start at the lower end of the dosing range.

Proper administration is critical for the efficacy of Eltrombopag Olamine.

1. 1Empty Stomach: Take the medication at least 1 hour before or 2 hours after eating.
2. 2The "4-Hour Rule": Do not take Eltrombopag within 4 hours of consuming any of the following: dairy products (milk, cheese, yogurt, ice cream), calcium-fortified juices, antacids containing aluminum or magnesium, or mineral supplements containing iron, zinc, or selenium. These substances bind to the drug and prevent it from entering the bloodstream.
3. 3Consistency: Take the dose at the same time every day to maintain steady levels in the blood.
4. 4Swallow Whole: Tablets should not be crushed or mixed with food, as this can alter the absorption rate.

If you miss a dose, skip the missed dose and take your next dose at the regularly scheduled time. Do not take two doses at once to make up for a missed one. Taking more than one dose in a 24-hour period increases the risk of serious side effects, including blood clots.

Signs of an Eltrombopag Olamine overdose may include an abnormally high platelet count, which significantly increases the risk of thromboembolic (clotting) events. Symptoms may include swelling in the legs, chest pain, or shortness of breath. In the event of a suspected overdose, seek emergency medical attention immediately. Healthcare providers will likely monitor platelet counts and may initiate treatment to prevent clotting.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking this medication without medical guidance, as your platelet counts may drop rapidly upon discontinuation.

Many patients taking Eltrombopag Olamine experience mild to moderate side effects as their body adjusts to the medication. According to clinical trial data, the most common side effects include:

• Nausea and Diarrhea: These gastrointestinal symptoms are frequent but often subside after the first few weeks of treatment. Taking the medication on a strictly empty stomach as directed can sometimes help manage nausea.
• Upper Respiratory Tract Infections: Patients may experience symptoms similar to the common cold, including sore throat, runny nose, or cough.
• Headache: This is one of the most frequently reported side effects. While usually mild, persistent or severe headaches should be reported to a doctor.
• Muscle Aches (Myalgia): Generalized body aches or specific pain in the back and extremities are common.

• Increased Liver Enzymes: Elevations in ALT, AST, and bilirubin are observed in a significant percentage of patients. This is why regular liver function testing is mandatory.
• Cataracts: Some patients have developed new or worsening cataracts (clouding of the lens in the eye) while taking Eltrombopag. Patients should have an eye exam before starting treatment and regular check-ups thereafter.
• Paresthesia: A sensation of tingling, tickling, or burning of the skin.
• Rash: Skin eruptions or itching (pruritus) may occur.

• Bone Marrow Fibrosis: There is a theoretical risk that stimulating the bone marrow over a long period could lead to the formation of scar tissue (reticulin fiber deposition). Doctors monitor for signs of this by checking blood smears for abnormalities.
• Thrombotic Microangiopathy: A rare but serious condition involving small blood clots in the capillaries.

> Warning: Stop taking Eltrombopag Olamine and call your doctor immediately if you experience any of the following symptoms of serious complications:

1. 1Liver Toxicity: Symptoms include yellowing of the skin or eyes (jaundice), dark-colored urine, unusual fatigue, or pain in the upper right side of the stomach area.
2. 2Blood Clots (Thromboembolism): Eltrombopag increases the risk of clots regardless of the platelet count. Seek emergency care for:

• Swelling, warmth, or tenderness in one leg (Deep Vein Thrombosis).
• Sudden shortness of breath or sharp chest pain (Pulmonary Embolism).
• Sudden weakness, especially on one side of the body, or difficulty speaking (Stroke).

1. 1Vision Changes: Any sudden blurring or loss of vision could indicate cataract progression or other ocular issues.

With prolonged use, the primary concerns are the development of cataracts and potential changes to the bone marrow architecture. Long-term data from the EXTEND trial suggested that while most patients tolerate the drug well for years, the risk of liver enzyme elevations persists throughout the duration of therapy. Additionally, there is a risk that the underlying disease (such as Myelodysplastic Syndrome) could progress to Acute Myeloid Leukemia (AML) if the drug is used in patients with pre-existing marrow abnormalities.

Eltrombopag Olamine carries a Black Box Warning for Hepatotoxicity. The drug may cause severe liver injury that can be fatal. In clinical trials, significant elevations in serum transaminases and bilirubin were observed. Healthcare providers must measure serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin before starting Eltrombopag, every 2 weeks during the dose adjustment phase, and monthly once a stable dose is reached. If levels are significantly elevated, the drug must be discontinued.

Report any unusual symptoms, especially those involving your vision, liver, or circulation, to your healthcare provider immediately.

Eltrombopag Olamine is a potent medication that requires careful clinical oversight. It is not a cure for ITP or aplastic anemia; rather, it is a management tool to keep platelet counts in a safe range. Patients must be aware that their platelet counts will likely drop back to baseline levels (or lower) within 1 to 2 weeks of stopping the medication, which can lead to a significant risk of bleeding.

Hepatotoxicity Risk: Eltrombopag Olamine can cause serious liver damage. Healthcare providers must perform liver function tests (ALT, AST, and bilirubin) prior to initiation, every 2 weeks during the dose titration phase, and monthly thereafter. If ALT levels increase to ≥3x the upper limit of normal (ULN), tests should be repeated within 3 to 5 days. If the levels remain high or continue to rise, the medication may need to be interrupted or permanently discontinued.

Thrombotic/Thromboembolic Complications

There is an increased risk of blood clots when taking Eltrombopag Olamine. This risk is not exclusively linked to high platelet counts; clots have occurred in patients with platelet counts within or even below the normal range. Patients with known risk factors for thromboembolism (e.g., Factor V Leiden, ATIII deficiency, or sedentary lifestyle) should be monitored with extreme caution.

Malignancy and Progression of MDS

Eltrombopag Olamine is not indicated for the treatment of Myelodysplastic Syndrome (MDS). There is a concern that TPO receptor agonists could stimulate the proliferation of malignant cells. In clinical trials of patients with MDS, Eltrombopag was associated with an increased risk of progression to Acute Myeloid Leukemia (AML).

Cataracts

As noted in animal studies and confirmed in human clinical trials, Eltrombopag is associated with the development and progression of cataracts. Baseline and regular ophthalmic examinations are recommended for all patients.

Patients on Eltrombopag Olamine must commit to a rigorous monitoring schedule:

• Complete Blood Counts (CBC): Weekly during the initial phase to monitor platelet response and adjust dosage. Once a stable dose is reached, CBCs are typically performed monthly.
• Liver Function Tests (LFTs): As detailed in the Black Box Warning, these are critical for preventing permanent liver damage.
• Peripheral Blood Smears: Periodically checked to look for new or worsening morphological abnormalities in blood cells that might suggest bone marrow fibrosis.

While Eltrombopag Olamine does not typically cause sedation, side effects like headaches or vision changes (cataracts) could potentially impair your ability to drive or operate heavy machinery safely. Assess your reaction to the medication before engaging in these activities.

There is no direct chemical interaction between alcohol and Eltrombopag. However, because both alcohol and Eltrombopag can stress the liver, patients are generally advised to limit alcohol consumption to avoid exacerbating potential hepatotoxicity.

If Eltrombopag Olamine is discontinued, the risk of bleeding is significantly increased because platelet counts will fall. This "rebound thrombocytopenia" can result in counts lower than the patient's original baseline. Healthcare providers will typically monitor CBCs weekly for at least 4 weeks after stopping the drug.

> Important: Discuss all your medical conditions, especially any history of liver disease or blood clots, with your healthcare provider before starting Eltrombopag Olamine.

There are no absolute drug-drug contraindications where the combination is strictly forbidden, but there are several that require such extreme caution that they are often avoided. The most significant concern is with Polyvalent Cation-containing products. While not a "combination" in the sense of two drugs interacting in the blood, taking Eltrombopag simultaneously with antacids (aluminum/magnesium), iron supplements, or calcium supplements will essentially neutralize the Eltrombopag, leading to treatment failure.

Statins (HMG-CoA Reductase Inhibitors)

Eltrombopag is an inhibitor of the OATP1B1 and BCRP transporters. This can lead to significantly increased plasma concentrations of certain statins, such as Rosuvastatin, Atorvastatin, and Simvastatin. Patients taking these combinations may have an increased risk of statin-induced myopathy and rhabdomyolysis (muscle breakdown). Healthcare providers may recommend reducing the statin dose by 50% when starting Eltrombopag.

BCRP Substrates

Drugs like Methotrexate, Topotecan, and Irinotecan are substrates of the Breast Cancer Resistance Protein (BCRP). Eltrombopag can increase the levels of these drugs, potentially increasing their toxicity. Close monitoring for side effects related to these medications is necessary.

CYP1A2 and CYP2C8 Inhibitors/Inducers

While Eltrombopag is metabolized by these enzymes, clinical studies suggest that inhibitors (like ciprofloxacin) or inducers (like rifampin) have a modest effect on Eltrombopag levels. However, caution is still advised, and platelet counts should be monitored more frequently if these drugs are started or stopped.

Dairy and Calcium

Consuming Eltrombopag with dairy products (milk, yogurt, cheese) or calcium-fortified foods can reduce the drug's absorption by over 70%. This interaction occurs in the digestive tract where calcium binds to the Eltrombopag molecule, creating a complex that the body cannot absorb.

High-Fat Meals

While the primary restriction is on minerals, a very high-fat meal can also slightly alter the absorption profile, though the effect is less dramatic than the mineral interaction. The recommendation remains to take the drug on an empty stomach.

• Iron, Zinc, and Magnesium Supplements: These must be spaced at least 4 hours apart from Eltrombopag for the same reasons as calcium.
• St. John’s Wort: As a potent inducer of various metabolic pathways, it may theoretically reduce the efficacy of Eltrombopag, though specific data is limited.

Eltrombopag is highly colored (reddish-brown). In some instances, it may interfere with certain laboratory tests that use colorimetric methods, such as serum bilirubin tests or creatinine tests. If lab results seem inconsistent with clinical findings, the laboratory should be notified that the patient is taking Eltrombopag.

For each major interaction, the management strategy usually involves either spacing the doses (for minerals) or reducing the dose of the interacting drug (for statins).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter antacids and multivitamins.

Eltrombopag Olamine is absolutely contraindicated in patients with a known hypersensitivity to Eltrombopag or any of its excipients. An allergic reaction could manifest as anaphylaxis, angioedema (swelling of the face or throat), or severe skin rashes. If a patient has previously experienced a severe reaction to this medication, it must never be used again.

Relative contraindications are conditions where the drug should only be used if the potential benefits outweigh the significant risks.

1. 1Pre-existing Hepatic Impairment: Patients with advanced cirrhosis or active liver disease are at much higher risk for Eltrombopag-induced hepatotoxicity. While not an absolute contraindication, it requires a reduced starting dose and intense monitoring.
2. 2Myelodysplastic Syndrome (MDS): Because of the risk of progression to Acute Myeloid Leukemia (AML), Eltrombopag is generally avoided in patients with MDS unless they are part of a specific clinical trial.
3. 3High Risk for Thromboembolism: Patients with a history of multiple blood clots, recent major surgery, or genetic clotting disorders should only use Eltrombopag if no other options exist, as the drug further increases the risk of life-threatening clots.
4. 4East Asian Ancestry: While not a contraindication, patients of East Asian descent require a mandatory dose reduction due to significantly higher systemic exposure (AUC) compared to Caucasian patients.

There is no known cross-sensitivity between Eltrombopag Olamine and other TPO receptor agonists like Romiplostim or Avatrombopag, as their chemical structures are distinct. However, if a patient has a history of severe immune-mediated reactions to other non-peptide drugs, they should be monitored closely for the first several doses.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of liver disease, blood clots, or cancer, before prescribing Eltrombopag Olamine.

Eltrombopag Olamine is classified as a medication that should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Animal studies have shown evidence of fetal toxicity, including reduced fetal body weight and an increased rate of cervical ribs at doses that were also toxic to the mother. There are no adequate and well-controlled studies in pregnant women.

• First Trimester: The risk of organogenesis disruption is highest; use is generally avoided.
• Third Trimester: Risk of neonatal thrombocytopenia or other hematologic issues if the drug crosses the placenta.
• Fertility: In animal studies, Eltrombopag did not affect female fertility but did show some effects on male reproductive organs at very high doses.

It is not known whether Eltrombopag is excreted in human milk. However, many drugs are excreted in milk, and because of the potential for serious adverse reactions in nursing infants (including liver toxicity and blood clots), breastfeeding is generally not recommended while taking Eltrombopag Olamine.

Eltrombopag is FDA-approved for the treatment of chronic ITP in children 1 year and older and for SAA in children 2 years and older. In pediatric clinical trials, the safety profile was generally similar to that in adults, though the incidence of upper respiratory tract infections and fever was higher in children. Long-term effects on growth and development have not been fully established, though no major signals have emerged in the years since its approval.

Clinical studies included a significant number of patients aged 65 and over. No overall differences in safety or effectiveness were observed between these patients and younger subjects. However, because older adults often have reduced hepatic, renal, or cardiac function and are frequently taking multiple other medications (polypharmacy), healthcare providers usually start at the lower end of the dosing range and monitor more frequently for interactions, particularly with statins.

Eltrombopag is not significantly cleared by the kidneys; therefore, no dose adjustment is required for patients with renal impairment. However, because some metabolites are excreted in the urine, patients with severe renal disease or those on dialysis should be monitored closely for any signs of unexpected toxicity.

This is a critical area for Eltrombopag. For patients with any degree of hepatic impairment (Child-Pugh Class A, B, or C), the starting dose must be reduced to 25 mg once daily. These patients are at a significantly higher risk for liver injury and must have their liver enzymes monitored weekly during the dose titration phase. If liver function worsens, the drug must be stopped.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.

Eltrombopag Olamine is a non-peptide thrombopoietin (TPO) receptor agonist. It targets the TPO receptor (c-Mpl), which is located on the surface of megakaryocytes and their progenitor cells. Unlike endogenous TPO, which binds to the extracellular domain of the receptor, Eltrombopag binds to the transmembrane domain. This binding triggers the activation of the Janus kinase (JAK) signaling pathway and the signal transducer and activator of transcription (STAT) pathway. The result is an increase in the proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, ultimately leading to an increase in platelet production.

• Dose-Response: There is a clear dose-dependent increase in platelet counts. In clinical trials, higher doses led to higher peak platelet counts.
• Time to Onset: Platelet counts typically begin to rise within 1 to 2 weeks of starting therapy.
• Duration of Effect: After stopping the drug, platelet counts usually return to baseline levels within 1 to 2 weeks.
• Tolerance: There is no evidence of the development of pharmacological tolerance; the drug remains effective over long periods of continuous use.

| Parameter | Value |

|---|---|

| Bioavailability | ≥52% (decreased by food/minerals) |

| Protein Binding | >99% (primarily to albumin) |

| Half-life | 21–32 hours |

| Tmax | 2–6 hours |

| Metabolism | CYP1A2, CYP2C8, UGT1A1, UGT1A3 |

| Excretion | Fecal 59%, Renal 31% |

• Molecular Formula: C25H22N4O4 · 2C2H7NO
• Molecular Weight: 564.6 g/mol (as olamine salt)
• Solubility: Practically insoluble in water; solubility is pH-dependent.
• Structure: It is a biphenylhydrazone derivative. The "olamine" part of the name refers to the ethanolamine salt form used to improve the stability and processing of the drug.

Eltrombopag Olamine is classified as a Thrombopoietin (TPO) Receptor Agonist. It is part of a small group of medications that includes Romiplostim (an injectable peptide) and Avatrombopag (another oral non-peptide). These drugs are distinct from other hematologic agents like erythropoiesis-stimulating agents (ESAs) or colony-stimulating factors (CSFs), as they specifically target the platelet lineage.